MX2019015502A - L-asparaginasa modificada. - Google Patents
L-asparaginasa modificada.Info
- Publication number
- MX2019015502A MX2019015502A MX2019015502A MX2019015502A MX2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A
- Authority
- MX
- Mexico
- Prior art keywords
- modified protein
- asparaginase
- poly
- modified
- amino acid
- Prior art date
Links
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 title abstract 4
- 108010024976 Asparaginase Proteins 0.000 title abstract 4
- 102000035118 modified proteins Human genes 0.000 abstract 5
- 108091005573 modified proteins Proteins 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 241000588698 Erwinia Species 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención hace referencia a una proteína modificada que es una combinación de (i) una L-asparaginasa y (ii) uno o más (poli)péptidos, donde el (poli)péptido consiste únicamente en residuos de aminoácidos de alanina y prolina. La proteína modificada puede formarse de una cantidad de formas, lo que incluye la conjugación química entre L-asparaginasa y los (poli)péptidos o la expresión de la proteína modificada como proteína de fusión. También se proporcionan en la presente ácidos nucleicos que codifican la proteína modificada, vectores y/o células hospedadoras que los comprenden, así como procesos para su producción. Se describen composiciones que comprenden la proteínamodificada y su uso en la medicina, particularmente en el tratamiento del cáncer. En otro aspecto de la invención, la L10 asparaginasa puede derivarse de Erwinia y/o tiene una identidad de al menos 85 % con respecto a la secuencia de aminoácidos de la SEQ ID NO:1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523061P | 2017-06-21 | 2017-06-21 | |
| EP17177237.9A EP3418383A1 (en) | 2017-06-21 | 2017-06-21 | Modified l-asparaginase |
| US15/671,086 US10174302B1 (en) | 2017-06-21 | 2017-08-07 | Modified L-asparaginase |
| PCT/EP2018/066647 WO2018234492A1 (en) | 2017-06-21 | 2018-06-21 | L-ASPARAGINASE MODIFIED |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015502A true MX2019015502A (es) | 2020-07-28 |
Family
ID=64737515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015502A MX2019015502A (es) | 2017-06-21 | 2018-06-21 | L-asparaginasa modificada. |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP3642340B1 (es) |
| JP (2) | JP2020528743A (es) |
| KR (1) | KR20200030065A (es) |
| CN (1) | CN111315878B (es) |
| AU (1) | AU2018287145B2 (es) |
| BR (1) | BR112019027479A2 (es) |
| CA (1) | CA3068100A1 (es) |
| DK (1) | DK3642340T3 (es) |
| FI (1) | FI3642340T3 (es) |
| IL (1) | IL271504B2 (es) |
| MX (1) | MX2019015502A (es) |
| SA (1) | SA519410870B1 (es) |
| SG (1) | SG11201912625QA (es) |
| WO (1) | WO2018234492A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3919623A1 (en) | 2015-12-22 | 2021-12-08 | XL-protein GmbH | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2019101308A1 (en) * | 2017-11-22 | 2019-05-31 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| JP2022522270A (ja) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物 |
| TW202241922A (zh) * | 2020-12-23 | 2022-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限公司 | 純化電荷遮蔽的融合蛋白質之方法 |
| US20220313798A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8519753D0 (en) * | 1985-08-06 | 1985-09-11 | Health Lab Service Board | Production of 1-asparaginase |
| WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| EP2851424B1 (en) * | 2007-03-09 | 2016-09-21 | Novozymes A/S | Thermostable asparaginases |
| DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
| WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| CN107496932A (zh) | 2012-02-27 | 2017-12-22 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
-
2018
- 2018-06-21 KR KR1020207002029A patent/KR20200030065A/ko not_active Application Discontinuation
- 2018-06-21 EP EP18731853.0A patent/EP3642340B1/en active Active
- 2018-06-21 AU AU2018287145A patent/AU2018287145B2/en active Active
- 2018-06-21 MX MX2019015502A patent/MX2019015502A/es unknown
- 2018-06-21 IL IL271504A patent/IL271504B2/en unknown
- 2018-06-21 CA CA3068100A patent/CA3068100A1/en active Pending
- 2018-06-21 CN CN201880054251.4A patent/CN111315878B/zh active Active
- 2018-06-21 EP EP22204187.3A patent/EP4180525A1/en active Pending
- 2018-06-21 WO PCT/EP2018/066647 patent/WO2018234492A1/en active Application Filing
- 2018-06-21 SG SG11201912625QA patent/SG11201912625QA/en unknown
- 2018-06-21 DK DK18731853.0T patent/DK3642340T3/da active
- 2018-06-21 BR BR112019027479-0A patent/BR112019027479A2/pt unknown
- 2018-06-21 JP JP2019571042A patent/JP2020528743A/ja active Pending
- 2018-06-21 FI FIEP18731853.0T patent/FI3642340T3/fi active
-
2019
- 2019-12-21 SA SA519410870A patent/SA519410870B1/ar unknown
-
2023
- 2023-02-28 JP JP2023030460A patent/JP2023081915A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111315878B (zh) | 2024-04-26 |
| IL271504A (en) | 2020-02-27 |
| EP4180525A1 (en) | 2023-05-17 |
| IL271504B2 (en) | 2024-05-01 |
| SA519410870B1 (ar) | 2023-03-06 |
| KR20200030065A (ko) | 2020-03-19 |
| JP2023081915A (ja) | 2023-06-13 |
| AU2018287145A1 (en) | 2020-02-06 |
| IL271504B1 (en) | 2024-01-01 |
| EP3642340B1 (en) | 2024-03-20 |
| RU2020101972A (ru) | 2021-07-21 |
| SG11201912625QA (en) | 2020-01-30 |
| RU2020101972A3 (es) | 2021-11-09 |
| AU2018287145B2 (en) | 2024-04-18 |
| CN111315878A (zh) | 2020-06-19 |
| FI3642340T3 (fi) | 2024-06-18 |
| JP2020528743A (ja) | 2020-10-01 |
| CA3068100A1 (en) | 2018-12-27 |
| BR112019027479A2 (pt) | 2020-09-15 |
| DK3642340T3 (da) | 2024-06-03 |
| EP3642340A1 (en) | 2020-04-29 |
| WO2018234492A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015502A (es) | L-asparaginasa modificada. | |
| EA201101553A1 (ru) | Полипептид, деградирующий углеводы, и его применения | |
| PH12018501628A1 (en) | Optimized factor viii genes | |
| WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
| MY176331A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| MX339277B (es) | Agente inductor de inmunidad. | |
| MY160897A (en) | Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof | |
| MX2012015142A (es) | Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo. | |
| GB201201178D0 (en) | Novel enzymes | |
| NZ603348A (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
| MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| WO2011036443A9 (en) | S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders | |
| PH12015500461A1 (en) | Novel il-17a binding molecules and medical uses thereof | |
| EP2589658A4 (en) | PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN | |
| WO2014202622A3 (en) | Rasamsonia gene and use thereof | |
| NZ609216A (en) | Anticancer fusion protein | |
| EP4306123A3 (en) | Saposin-a derived peptides and uses thereof | |
| MX2020012332A (es) | Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo. | |
| PH12017502323A1 (en) | Novel xylanase | |
| EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
| MY195726A (en) | Steviol Glycoside Transport | |
| IN2014DN09963A (es) | ||
| AR071534A1 (es) | Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa | |
| RU2013111675A (ru) | Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc | |
| EA201300059A1 (ru) | Полипептид, обладающий активностью сволленина, и его применение |